Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Biotech ETF Index Surges 10% After Rebalance

BY | ETF Database
7:05 am ET 06/25/26 | 21 VIEWS
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO B-) gained over 10% in just six trading days beginning June 18.Key Takeaways: SBIO’s underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance. Thirty-seven companies were added and 15 removed, making it one of the index’s largest reconstitutions in recent memory. Apogee and Definium alone accounted for nearly 2.88 percentage points of the index’s 10.01% total gain. SBIO tracks the S-Network Medical Breakthroughs Index, which requires holdings to have at least one drug candidate in Phase II or Phase III FDA clinical trials. Companies must also carry enough cash to keep operating for at least 24 months, a screen designed to filter out firms at risk of running out of funding before a trial concludes. For investors tracking small-cap biotech through a fund like SBIO, the June reconstitution illustrates how quickly index rules can reshape a portfolio and drive outsized moves. See more: Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A Thirty-seven companies entered the index and 15 departed on June 18, according to VettaFi data. Departures included some of the index’s largest prior positions. Alkermes (ALKS) had carried a 4.75% weight, Kymera Therapeutics, Inc. (KYMR) sat at 4.67%, Spyre Therapeutics, Inc. (SYRE) at 4.39%, and Mirum Pharmaceuticals, Inc. (MIRM) at 4.09%, according to VettaFi data. Among the 37 new additions, the largest initial positions went to Veradermics Inc. (MANE) at 2.43%, Dyne Therapeutics Inc. (DYN) at 2.03%, Definium Therapeutics Inc. (DFTX) at 1.66%, and Kailera Therapeutics Inc. (KLRA) at 1.6%, according to VettaFi.Breaking Down the Biotech Index GainsApogee Therapeutics, Inc. (APGE), an existing holding, led all contributors during the six-day window. It carried the highest average weight in the index at 4.34%, climbed 46.8%, and contributed 1.68 percentage points to the total return, according to VettaFi data. Two new additions also drove gains. Definium entered at a 1.66% weight on June 18 and surged 72.1% in six days, adding 1.2 percentage points to the return. Its average weight during the period rose to 2.09%, above its initial entry weight, as price gains pushed its market value higher within the index. Veradermics, also added June 18, climbed nearly 25% from its 2.43% starting weight and contributed 0.59 percentage points, the data showed. SBIO holds $170.4 million in assets and carries a 0.50% expense ratio, according to ETF Database. For more news, information, and analysis, visit the ETF Building Blocks Content Hub. VettaFi LLC (“VettaFi”) is the index provider for SBIO, for which it receives an index licensing fee. However, SBIO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of SBIO.

More Commentary

What Rising Structural Inflation Means for Your Bond Portfolio
BY | ETF Database
8:53 am ET 06/25/26 | 24 VIEWS
ROBO & THNQ Rebalance Weight Toward AI Backbones & Physical Automation
BY | ETF Database
8:29 am ET 06/25/26 | 27 VIEWS
Why AI Spending Is Favoring Industrials & Utilities
BY | ETF Database
7:19 am ET 06/25/26 | 26 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.